Skip to navigation Skip to content

Tyruko

Share

About this Medication
  • Brand Name: Tyruko® (tie-ROO-koh) (natalizuman-sztn, biosimilar to Tysabri)
  • Chemical Name: natalizumab-sztn (na-ta-lie-zoo-mab-sztn)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is given by IV infusion.

Description

Tyruko® is biosimilar to Tysabri®. It is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.

Tyruko is approved by the U.S. Food and Drug Administration (FDA) as a monotherapy (not to be used in combination with other disease-modifying therapies) for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Click here to read the Tysabri Prescribing Information and Medication Guide.

Support

Sandoz
1-800-525-8747

Financial Assistance Program

No patient assistance program available at this time.

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.